Material Modification to Rights of Security Holders. The information set forth in

CEO and President — Mr. Jun Liu: The CEO Agreement provides for the continuation of Mr. Liu's services as Chief Executive Officer and President with a defined term and conditions.

Entry into a Material Definitive Agreement The information set forth below under

Chief Financial Officer and Treasurer — Haiyan Yang: Ms. Haiyan Yang resigned as Chief Financial Officer and Treasurer, with Wanjun Zhang appointed to replace her.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 5, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which…

Unregistered Sales of Equity Securities;. On September 25, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”), issued 28,312 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to Xiaohong Song, an investor that entered into Amended and Restated Subscription Agreement with the Company on November 27, 2024 (the “Agreement”). In accordance with the terms of the Agreement, in consideration of $200,000 subscribed for by Mr. So…

Entry into a Material Definitive Agreement. On August 25, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Dominari Securities, LLC, as representative of the underwriters named on Schedule I therein, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten initial public offering (the “Offering”) an aggregate of 3,750,000 shares of the Company’s common s…